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Abstract 
Background: Tacrolimus is one of the most widely used liver transplant medications. With 
the increasing number of obese patients requiring liver transplants, knowledge of the effect of 
body size affecting post-transplant outcomes e.g. drug exposure is increasingly required.  
Aims: 1) To investigate whether patient body size (i.e. total body weight) affect trough 
plasma concentrations of tacrolimus when a standard mg/kg dosing regimen is used; 2) To 
investigate whether obese patients have different number of plasma concentrations outside 
the therapeutic range compared to the non-obese patients in the first months after liver 
transplant. 
Methods: Using a transplant database, data tacrolimus concentrations were available for 69 
patients. Tacrolimus was initially dosed at a standard 0.1mg/kg/day after liver transplant, and 
adjusted to maintain a target trough concentration. Trough blood samples, phenotypic and 
outcome variables were analysed.  
Results: Trough concentrations were similar between the obese and non-obese patients 
(p>0.05) at each sampling day. At day-7 post-transplant, 85.7% and 79.5% of the observed 
plasma concentrations were outside the recommended therapeutic range for the obese and the 
non-obese patients respectively; at day-30, 52.9% and 57.4% and at 6 months, 18.7% and 
27.5%.  
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Conclusions: In the first week post-transplant, tacrolimus trough concentrations after 
standard mg/kg dosing post liver transplant appear to be corrected by total body weight. 
Obese patients have similar number of trough plasma concentrations outside the therapeutic 
range compared to the non-obese patients.  
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Introduction 
 
With the increasing proportion and number of obese patients requiring liver transplants
1
, 
knowledge of the effect of obesity on factors affecting postoperative outcomes is increasingly 
required. Specifically, the effect of different transplant medication regimens based on an 
individual’s body size and composition appears relevant. However, isolating the effects of 
one factor on outcomes can be difficult in this complex setting. Assessing efficacy and 
toxicity of drug dosing choices and regimens is one such occasion whereby measuring 
clinical outcomes are preferred. However, such studies are often expensive, have slow 
recruitment due to paucity of numbers and time-consuming in terms of long-term follow-up. 
Fortunately, drug exposure via measurement of appropriately timed plasma concentrations 
are correlated with clinical outcomes for many transplant drugs
2-5
 and have become an 
accepted tool to guide dosing in this setting. Therefore, plasma drug concentrations are used 
as a surrogate marker for therapeutic efficacy
6-8
. Tacrolimus is one of the most widely used 
liver transplant medications, with efficacy and toxicity correlated with drug exposure.  
 
In this work, we aimed to describe tacrolimus dose and plasma concentrations based on a 
sequential cohort of liver transplant patients. Specifically, we aimed to investigate 1) whether 
patient body size parameters affect trough plasma concentrations of tacrolimus when a 
standard mg/kg dosing regimen is used (dosing is based on the patient’s total body weight) 
and 2) whether obese patients have different number of plasma concentrations outside the 
therapeutic range compared to the non-obese patients. Although numbers of poor outcomes 
are now relatively few with liver transplant in comparison to other transplanted organs, we 
aimed also to describe any relationship between obesity and/or plasma concentrations and 
elevated liver function, infection and other reported adverse events. 
 
Methods 
 
We undertook this single-centre retrospective study at the Princess Alexandra Hospital, 
Queensland, a tertiary hospital that undertakes more than 50 liver transplants per year
9
. With 
low risk ethics approval, medical records for patients having a liver transplant between years 
2013 and 2014 were collected from 69 liver transplant recipients from the Transplant eVici 
database located in the Queensland Liver Transplant Service based at that Hospital. 
 
Tacrolimus (Prograf®; Janssen-Cilag, Dublin, Ireland) was dosed at 0.1mg/kg/day to start for 
all patients, and then adjusted to maintain a target trough concentration: 8-10ng/ml during the 
first three months after transplant; 5-8ng/ml between three to twelve months; 3-5ng/ml after 
twelve months. Blood samples (i.e. trough concentrations) were collected every day from the 
2
nd
 day after the transplant operation for 13 days continuously. For the purposes of this study, 
additional blood sample results at 1, 3, and 6 months post-transplant were also collected and 
reviewed. Blood samples were collected before dosing in the morning. The blood samples 
were analyzed with a high performance liquid chromatography tandem mass spectroscopy 
method previously published
10
. This assay is specific for the parent drug tacrolimus; is linear 
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over the range of 0.5–50 ng ml−1 (r2 > 0.99) and has a within- and between-day imprecision 
of <8%. 
 
A Pearson correlation coefficient test was applied in R to assess the correlation between the 
tacrolimus plasma concentrations and surrogate clinical outcomes (e.g. liver function). 
Student’s t-test was used for calculating the p-value to investigate the statistical difference 
between two groups.  
 
Results  
 
Patient demographic data is presented in Table 1. 20 of the 69 patients were categorized as 
obese (BMI>30kg/m
2
).  
In Table 2, median values and range of tacrolimus plasma trough concentrations at different 
sampling days are presented for obese and non-obese patients respectively. The trough 
concentrations are similar between the obese and non-obese patients (p>0.05) at each 
sampling day. Figure 1 shows the trough concentrations of the obese and the non-obese 
groups at each time point. 
 
Figure 1. Tacrolimus plasma concentration after liver transplant for non-obese as “o” and 
obese patients as “x”. Dotted line and solid line represent the median values of obese and 
non-obese patients respectively. “2d” and “1m” indicate 2 days and 1 month after the 
transplant separately.  
 
In clinical practice, the therapeutic range aimed for to reduce toxicity and reduce rejection is 
8-10ng/ml during the first three months after transplant; 5-8ng/ml after three months; 3-
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5ng/ml after twelve months. For the observations crossing all the sampling time points, 72.6% 
(170 observations out of 234) and 70.2% (420 observations out of 598) of the observed 
plasma concentrations are outside the range for the obese and the non-obese patients 
respectively. At the specific sampling time points (i.e. day-7 and day-30 as clinically relevant 
time points for rejection), at day-7: 85.7% (12 observations out of 14) and 79.5% (31 
observations out of 39) of the observed plasma concentrations are outside the range for the 
obese and the non-obese patients respectively; at day-30: 52.9% (8 observation out of 17) and 
57.4% (27 observations out of 47) of the observed plasma concentrations are outside the 
range for the obese and the non-obese patients respectively; at 6 months: 18.7% (3 
observation out of 16) and 27.5% (11 observations out of 40) of the observed plasma 
concentrations are outside the range for the obese and the non-obese patients respectively. 
 
Figures in Appendix 1, describe the liver function test results (Total Bilirubin, ALP, GGT, 
ALT and AST) between the obese and the non-obese patients separately. The figure in 
Appendix 2, describes the relationship between tacrolimus concentration and renal function 
(i.e. creatinine concentrations) in both obese and non-obese patients. Figures in Appendix 3, 
describe the possible correlations between the tacrolimus plasma concentrations and liver 
function indicators.  
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Discussion 
 
This was a retrospective study of a large liver transplant patient cohort, examining the 
relationship of body size to trough concentrations when dosing is given at a set amount per kg 
total body weight. Exploratory analysis of the relationship between concentrations and 
efficacy/toxicity was also undertaken to guide future work. 
 
The major finding of this Study is summarised in Figure 1. This shows that the trough 
concentrations overlap at each day for the obese and the non-obese patients. This suggests 
that the trough concentrations between the two groups are similar regardless of body size 
when dosed on the recommended algorithm. Similarly, it is also observed that number of 
plasma concentrations outside the therapeutic range are similar between the obese and the 
non-obese patients. Appendix 1 shows the relationship of liver function for the obese and the 
non-obese patients separately. The clinical observations mix well between the obese and the 
non-obese patients, suggesting that the influence of dosing on unit of patient body size 
appears appropriate from this retrospective audit. Appendix 2 shows that there appear to be 
no correlation between tacrolimus concentrations and renal toxicity in either the obese or the 
non-obese patients, regardless of the tacrolimus concentrations (i.e. high or low).  Also it 
shows that renal toxicity is similar between obese and non-obese patients. There appear also 
no correlations between the tacrolimus plasma concentrations and liver function indicators 
(Appendix 3). 
 
Despite our findings it has been reported frequently that tacrolimus pharmacokinetics are 
related to patients’ body size11-14. Our observation is thus dissimilar as we suggest there 
appears no significant difference in trough concentrations of tacrolimus between groups with 
different body sizes when dosed on a mg/kg dosing regimen. Our speculation is that the 
discrepancy is explained by the fact that the random trough concentrations might not identify 
the body size effect appropriately, particularly as our two groups were discrete and did not 
examine body size as a continuous variable. More importantly, a random trough 
concentration may not be very representative for the complete pharmacokinetics of 
tacrolimus. This latter hypothesis is supported with renal transplant data with tacrolimus, 
showing that using the trough concentration alone to guide tacrolimus dosage adjustment can 
be misleading 
15-18
. Trevillian reported that 57.5% of kidney transplant patients in their study 
were overexposed to tacrolimus despite acceptable trough concentrations in the majority, 
resulting in significant toxicity. Further, particularly in the renal literature a derived AUC 
measurement has been shown to be a more accurate guide than trough concentrations for 
tacrolimus dose adjustments
15
.  
 
Body mass index (BMI) was the only parameter recorded in our study to describe the 
patient’s body size. BMI might not be an appropriate pharmacological parameter to 
categorize the patients into non-obese and obese groups (e.g. for those with end-stage liver 
disease due to ascites and sarcopenia).  Han
19
 reported in their kidney transplant study there 
were no statistical differences in pharmacokinetic profiles between groups with different 
BMIs. However, significant difference in pharmacokinetics was observed between groups 
once specific body composition values estimated by bioelectrical impedance analysis (e.g. 
lean mass, fat mass etc.) were used. 
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Based on the current study, we propose further investigations to elicit this relationship more 
fully by 1) conducting tacrolimus concentration monitoring with more after-dose blood 
samples and estimate the total drug exposure (i.e. AUC), subsequently to analyse the 
relationship between the body size and AUC; 2) to utilize distinct body composition related 
parameters to categorize the patients into different body size groups and then identify the 
body size effect; 3) further work needs to be undertaken in the period > 30 days post-
transplant.  
 
Conclusion 
 
This retrospective study describes the characteristics and drug exposure of a population of 
liver transplant patients prescribed tacrolimus. Although 30% of recipients were classified as 
obese, this did not appear to affect their pharmacokinetics nor toxicity profile. Specifically, 
tacrolimus trough concentrations after standard mg/kg dosing post liver transplant are not 
affected by total body weight. Nor does obesity affect time to the therapeutic concentrations, 
nor the clinical outcomes. No obvious correlations were observed between the tacrolimus 
plasma concentrations and the clinical outcomes. 
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Reference 
1. Anna J. Dare, Lindsay D. Plank, Anthony R.J. Phillips, Edward J. Gane, Barry Harrison, 
David Orr, Yannan Jiang, Adam S.J.R. Bartlett. The additive effect of pre-transplant obesity, 
diabetes and cardiovascular risk factors on outcome after liver transplantation. Liver 
Transplantation, 2014; DOI: 10.1002/lt.23818 
 
2. Jain AB, Todo S, Fung JJ et al. Correlation of rejection episodes with FK506 dosage, 
FK506 level, and steroids following primary orthotopic liver transplant. Transplant Proc 1991; 
23: 3023–3025. 
3. Backman L, Nicar M, Levy M et al. FK506 trough levels in whole blood and plasma in 
liver transplant recipients: correlation with clinical events and side effects. Transplantation 
1994; 57: 519–525. 
4. Schwarts M, Holst B, Facklam D et al. FK 506 in liver transplantation: correlation of 
whole blood levels with efficacy and toxicity. Transplant Proc 1995; 27: 1107. 
5. Undre N, van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates 
with acute rejection. Transplant Proc1999; 31: 296–298. 
6.Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in 
solid organ transplant recipients. Clinical pharmacokinetics. 2007;46(1):13-58. Epub 
2007/01/05. 
7.Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al. 
Pharmacokinetics of tacrolimus in liver transplant patients&ast. Clinical Pharmacology & 
Therapeutics. 1995;57(3):281-90. 
8.Jain A, FJ HI, Zuckerman S. Use of mycophenolate mofetil for tacrolimus related chronic 
nephrotoxicity in liver transplantation recipients. American Association for the Study of 
Liver Diseases. Hepatology. 1997;29:235a. 
9. https://metrosouth.health.qld.gov.au/transplant 
10. Taylor PJ, Brown SR, Cooper DP, Lynch SV. PI P. A high-throughput HPLC-MS/MS 
method for tacrolimus measurement. Ther Drug Monit. 2005; 27: 256. 
11. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in 
solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-653. 
 
12. Yasuhara M, Hashida T, Toraguchi M, et al. Pharmacokinetics and pharmacodynamics of 
FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant 
Proc 1995; 27 (1): 1108-10 
 
13. Sam WJ, Aw M, Quak SH, et al. Population pharmacokinetics of tacrolimus in Asian 
paediatric liver transplant patients. Br J Clin Pharmacol 2000; 50 (6): 531-41 
 
14. Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. Covariate effects on the 
apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion 
therapy. Clin Pharmacokinet 2001; 40 (1): 63-71 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
15. Trevillian P, Heer M, Ainsworth S, Hibberd A. Population Pharmacokinetic Profiling of 
Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem. [abstract]. Am J 
Transplant. 2017; 17 (suppl 3).  
 
16. Schiff, J., Cole, E., & Cantarovich, M. (2007). Therapeutic monitoring of calcineurin 
inhibitors for the nephrologist. Clinical Journal of the American Society of Nephrology, 2(2), 
374-384. 
 
17. Kim, I. W., Noh, H., Ji, E., Han, N., Hong, S. H., Ha, J., ... & Oh, J. M. (2012). 
Identification of factors affecting tacrolimus level and 5‐ Year clinical outcome in kidney 
transplant patients. Basic & Clinical Pharmacology & Toxicology, 111(4), 217-223. 
 
18. Scholten, E. M., Cremers, S. C., Schoemaker, R. I. K. C., Rowshani, A. T., van Kan, E. J., 
den Hartigh, J. A. N., ... & de Fijter, J. W. (2005). AUC-guided dosing of tacrolimus prevents 
progressive systemic overexposure in renal transplant recipients. Kidney International, 67(6), 
2440-2447. 
 
19. Han, S. S., Kim, D. H., Lee, S. M., Han, N. Y., Oh, J. M., Ha, J., & Kim, Y. S. (2012). 
Pharmacokinetics of tacrolimus according to body composition in recipients of kidney 
transplants. Kidney Research and Clinical Practice, 31(3), 157-162. 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Appendix 1. 
  
Figure A1.1 Total Bilirubin concentration after liver transplant operation (non-obese as “o” 
vs. obese as “x”). Dotted line and solid line represent the median values of obese and non-
obese patients respectively. 
 
 
 
Figure A1.2 ALP concentration after liver transplant operation (non-obese as “o” vs. obese as 
“x”). Dotted line and solid line represent the median values of obese and non-obese patients 
respectively. 
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Figure A1.3 GGT concentrations after liver transplant operation (non-obese as “o” vs. obese 
as “x”). Dotted line and solid line represent the median values of obese and non-obese 
patients respectively. 
 
 
Figure A1.4 ALT concentrations after liver transplant operation (non-obese as “o” vs. obese 
as “x”). Dotted line and solid line represent the median values of obese and non-obese 
patients respectively. 
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Figure A1.5 AST concentrations after liver transplant operation (non-obese as “o” vs. obese 
as “x”). Dotted line and solid line represent the median values of obese and non-obese 
patients respectively. 
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Appendix 2. 
 
Figure A2.1 Creatinine concentration (umol/L) after liver transplant operation v.s. tacrolimus 
concentrations of non-obese and obese patients. (non-obese as “o” and obese as “x”).  
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Appendix 3. 
 
  
Figure A3.1 Tacrolimus concentration vs. Total Bilirubin, r=0.016, p=0.63 
 
 
Figure A3.2 Tacrolimus concentration vs. ALP, r=-0.026, p=0.45 
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Figure A3.3 Tacrolimus concentration vs. GGT, r=0.18, p<0.0001 
 
  
Figure A3.4 Tacrolimus concentration vs. AST, r=0.14, p<0.0001 
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Figure A3.5 Tacrolimus concentration vs. ALT, r=0.12, p=0.0006 
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Table 1. Patient characteristics 
  No. median min max  1st Qu. 3rd Qu. 
Patient 69 - - - - - 
Age (year) - 53 34 66 50 57 
Gender 53(m)/16(f) - - - - - 
Obese 20 - - - - - 
BMI (kg) - 26 19 40 25 30 
Average Daily Dose (mg) - 9.2 2 18 7.6 11.5 
Time to stable concentration (day) - 5 0 13 3 9 
Death 11 - - - - - 
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Table 2. Tacrolimus plasma trough concentrations (ng/ml) after liver transplant (non-
obese vs. obese) 
 
obese patients (n=20) 
 
non-obese patients (n=49) 
 Time median min 1st Qu. 3rd Qu. max 
 
median min 1st Qu. 3rd Qu. max p-value 
2d 7.1 0 4.9 15.1 33.7 
 
7.9 0.6 5.8 13.3 19.8 0.65 
3d 8.1 0 5.4 10.8 23.6 
 
8.7 2 6.2 13.6 21.7 0.86 
4d 9.1 0 6.8 12.3 31.5 
 
9.1 1.5 6.8 11.3 17.7 0.37 
5d 6.4 0 4.6 9.5 22.7 
 
6.4 1.8 4.9 7.6 11 0.17 
6d 6 0 4.2 10.2 18.8 
 
5.5 1.4 4.3 6.2 12 0.13 
7d 5.9 0.9 5.1 7.9 15.7 
 
6.3 2 4.85 8.2 18.2 0.89 
8d 7.6 3.8 5.7 7.9 14.1 
 
5.8 2.9 5.2 7.8 17.3 0.59 
9d 6.3 3.9 5.6 6.9 15.7 
 
7.5 3.3 5.5 9.7 20.7 0.28 
10d 7 4.3 5.4 9.4 14.4 
 
8.3 1.8 6.7 9.7 18.6 0.49 
11d 6.5 3.7 4.5 9.1 12.2 
 
8 5.1 6.9 9.1 12.2 0.14 
12d 7.4 2.6 5.9 8.9 11.2 
 
7.9 5.3 6.2 8.9 11 0.66 
13d 6.1 3.2 5.3 8.4 11 
 
7.8 4.6 6.4 8.8 10.5 0.15 
14d 6.4 4.3 5.9 7.5 10.2 
 
7.5 2.5 6.6 8.6 15.2 0.09 
1m 8.6 2.9 6.8 9.5 12 
 
8.2 4.5 6.4 9.1 11 0.58 
3m 7.6 3.4 5.4 9 10.2 
 
8.6 4.2 7.4 9.2 14.4 0.12 
6m 6.7 3.2 6.2 6.9 8.4 
 
6.9 3.4 6.3 7.8 11.7 0.19 
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